


## AMENDMENTS

1. (Currently Amended) A compound of general formula A-(Y-ONO<sub>2</sub>)<sub>s</sub> (I) and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof, wherein


s is an integer equal to 1;

A is selected from the following  $\beta$ -adrenergic blockers residues of formula (II):




wherein

R<sub>1</sub> is



(IIb)

R<sub>2</sub> is



(IIIa) ;

Z is  $-\text{C}(\text{O})-\text{[.,.]}-\text{C}(\text{O})-$ ;

Z<sub>1</sub> is H;


Y is a bivalent radical having the following meaning selected from the group

consisting of:

a)

- straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO<sub>2</sub> or T, wherein T is -OC(O)(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>, -O(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>;

b)



wherein:

n is an integer from 0 to 20,

n1 is an integer from 1 to 20;


n2, n3, n4 and n5 are integers equal or different from each other, equal to 0 or 1,

R<sup>3</sup> and R<sup>4</sup> are independently selected from H or CH<sub>3</sub>,


Y<sup>1</sup> is -CH<sub>2</sub>- or -(CH<sub>2</sub>)<sub>na</sub>-CH=CH- wherein na is an integer from 0 to 20;

X<sub>1</sub> is -WC(O)- or -C(O)W-, wherein W is oxygen, sulfur or NH; and

c)



(VI)



(VI)

wherein

$X_2$  is O or S,

n10a, n10 and n12 are integer independently selected from 0 to 20,

n11 is an integer from 0 to 6;


R<sup>11</sup> is H, CH<sub>3</sub> or nitrooxy group;

$R^{11a}$  is  $CH_3$  or nitrooxy group;

and wherein  $(Y-ONO_2)_s$  bonds with Z and/or  $[[Z1]] \underline{Z_1}$  of formula (II).

Claims 2-3. (Cancelled).

4. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[3]] 1 wherein Y is a straight or branched C<sub>1</sub>-C<sub>10</sub> alkylene.
5. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein Y is



(iv)


wherein


n is an integer from 0 to 20,

n1 is an integer from 1 to 20;

n2, n3, n4 and n5 are integers equal or different from each other, equal to 0 or 1;  
R<sup>3</sup> and R<sup>4</sup> are independently selected from H or CH<sub>3</sub>;  
Y<sup>1</sup> is -(CH<sub>2</sub>)<sub>na</sub>-CH=CH- wherein na is an integer from 0 to 20;  
X<sub>1</sub> is -WC(O)- or -C(O)W-, wherein W is oxygen, sulfur or NH.

6. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein n2, n3, n4, n5 are equal to 0,  
n1 is 1,  
n is an integer from 0 to 10,  
Y<sup>1</sup> is CH<sub>2</sub>.
7. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein n, n2, n5 are 1,  
n3 and n4 are equal to 0, and  
n1 is an integer from 1 to 10,  
Y<sup>1</sup> is -(CH<sub>2</sub>)<sub>na</sub>-CH=CH- wherein na is 0,  
X<sub>1</sub> is -WC(O)- wherein W is oxygen and X<sub>1</sub> is bound to the phenyl ring through the [C]<sub>4</sub>,  
R<sup>4</sup> is CH<sub>3</sub> and the group (OR<sup>4</sup>) is bound to the phenyl ring through the [C]<sub>3</sub>.
8. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein Y is





wherein

$\text{X}_2$  is O or S,


$n10a$ ,  $n10$  and  $n12$  are integers independently selected from 0 to 20;

$n11$  is an integer from 0 to 6;

$\text{R}^{11}$  is H,  $\text{CH}_3$  or a nitrooxy group;

$\text{R}^{11a}$  is  $\text{CH}_3$  or a nitrooxy group.

9. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 8 wherein  
 $\text{Y}$  is



wherein

$\text{X}_2$  is O or S,

$n10a$  is an integer from 0 to 10

$n11$  are 0,

$n12$  is an integer from 1 to 10,

$\text{R}^{11}$  is H or a nitrooxy group;

wherein the  $-\text{ONO}_2$  group is bound to the  $-(\text{CH}_2)_{n12}$  group.


Claims 10-57. (Cancelled).

58. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 1 wherein Y is a straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene being optionally substituted with one or more of the substituents selected from the group consisting of halogen atoms, hydroxy, -ONO<sub>2</sub> or T, wherein T is -OC(O)(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>, -O(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>.


59. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 58 wherein Y is a straight or branched C<sub>3</sub>-C<sub>6</sub> alkylene.

Claims 60-80. (Canceled).


81. (Currently Amended) Compounds and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to any one of claims 1, 58 or 59 wherein the compounds are:




(1)




(4)




(7)



(8)



(9)



Claims 82-87. (Canceled).

88. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to claim 1, that is 4-(Nitrooxymethyl)benzoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanoate.

Claims 89-90. (Canceled).

91. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to any one of claims 1, 58 or 59, that is 6-(nitrooxy)hexanoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol hydrochloride.

Claims 92-94. (Canceled).

95. (Currently Amended) A medicament comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in any of claims claim 1 to 94 for use as medicament.

96. (Currently Amended) A method for the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases using Use of a drug comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in any of claims claim 1 to 94 for preparing a drug that can be employed in the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases.

97. (Currently Amended) A method for the treatment of glaucoma and elevated intraocular pressure using Use of a drug comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in any of claims claim 1 to 94 for preparing a drug that can be employed in the treatment of glaucoma and elevated intraocular pressure.

98. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in any of claims claim 1 to 94 and at least one pharmaceutical pharmaceutically acceptable carrier.